CONNECT WITH US
HealthTech

HealthTech

'Digital twins' of immune system in pregnancy identify drugs to prevent early labor

Medical Xpress logo

Published on

Add as a preferred source on Google
'Digital twins' of immune system in pregnancy identify drugs to prevent early labor

This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

Researchers have identified two common drugs that may, when given together during pregnancy, prevent premature births. The finding is the fruit of a new Stanford Medicine–led, artificial intelligence–powered technique for screening drugs to prevent early labor. It uses a comprehensive atlas of the immune system, which the researchers built to be accurate at a cell-by-cell level, to create "digital twins" of the immune systems of individual pregnant women for virtual drug testing.

The study, published in Science Advances, builds on two decades of Stanford Medicine research on how the maternal immune system shifts during pregnancy. When the immune clock of pregnancy runs too quickly, preterm labor can result.

Being born prematurely, meaning three or more weeks before the due date, carries a host of risks for the baby. Prematurity is now the leading cause of death in children under age 5 worldwide.

After screening several possible treatments with the digital twin system, the researchers identified one drug combination that promises to markedly lower the risk of early labor. It shows so much potential for averting preterm birth that researchers are starting a clinical trial in real patients.

, professor of anesthesiology, perioperative and pain medicine. It's been decades since there was a new pharmacological intervention for preventing preterm birth, he noted.



Source link

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.